Neither Outcomes4Me nor any participants in or contributors to any webinar, article or content endorses or recommends any products or services. Consult your physician regarding any treatment or therapy.
SABCS always brings major updates in early breast cancer including new data, new trials and new insights that directly shape patient care. In this live one-hour session, Dr. Kelly McCann breaks down the most important findings from this year’s meeting in a way that’s clear, practical and patient-focused.
What we cover:
- Key SABCS updates in early-stage HR-positive, HER2-positive and triple-negative breast cancer
- What’s coming next in targeted therapy and immunotherapy
- How to interpret research updates when talking with your own oncologist
- And more!
About Dr. Kelly McCann:
Kelly E. McCann, MD, PhD, is a board-certified hematologist-oncologist and translational researcher at UCLA Health, where she specializes in early-stage breast cancer and gynecologic cancers. She practices in Santa Monica and Beverly Hills and is an active member of Dr. Dennis Slamon’s Translational Oncology Research Laboratory, focusing on genetic and molecular drivers of cancer to advance targeted therapies. Dr. McCann completed her MD and PhD in cancer biology at Stanford University’s MSTP program, residency at OHSU, and fellowship at UCLA. Her dual background in engineering, cancer biology and clinical oncology enables her to bring a true bench-to-bedside perspective to patient care and clinical research.
